This research report provides a comprehensive analysis of the Drugs for Anti-Infective market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Drugs for Anti-Infective market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Drugs for Anti-Infective, challenges faced by the industry, and potential opportunities for market players.
The global Drugs for Anti-Infective market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Drugs for Anti-Infective market presents opportunities for various stakeholders, including Hospital, Drugs Store. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Drugs for Anti-Infective market. Additionally, the growing consumer demand present avenues for market expansion.
The global Drugs for Anti-Infective market was valued at US$ 203100 million in 2023 and is projected to reach US$ 259350 million by 2030, at a CAGR of 3.6% during the forecast period.
The Anti-Infective Drugs market refers to the pharmaceuticals and medications used for the treatment of infectious diseases caused by bacteria, viruses, fungi, or parasites. This market encompasses various therapeutic areas such as antibiotics, antivirals, antifungals, and antiparasitics. The Anti-Infective Drugs market has been witnessing steady growth due to factors such as the increasing prevalence of infectious diseases, the emergence of drug-resistant strains, and the growing global population. Key players in the market include pharmaceutical companies, biotechnology firms, and generic drug manufacturers. Geographically, North America currently holds a significant market share, but the market in Asia Pacific is expected to witness substantial growth in the coming years.
Key Features:
The research report on the Drugs for Anti-Infective market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Drugs for Anti-Infective market.
Market Overview: The report provides a comprehensive overview of the Drugs for Anti-Infective market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., OTC, Rx Drugs), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Drugs for Anti-Infective market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Drugs for Anti-Infective market's trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Drugs for Anti-Infective market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Drugs for Anti-Infective market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Drugs for Anti-Infective market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Drugs for Anti-Infective market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Drugs for Anti-Infective, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Drugs for Anti-Infective market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Drugs for Anti-Infective market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
OTC
Rx Drugs
Market segment by Application
Hospital
Drugs Store
Other
Global Drugs for Anti-Infective Market Segment Percentages, By Region and Country, 2023 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
GlaxoSmithKline
Merck
Pfizer
Novartis AG
Gilead Sciences
Abbott
Sanofi-Aventis
Bristol-Myers Squibb
Johnson
Roche Pharma AG
Nanosphere
NanoViricides
Novabay Pharmaceuticals
Obetech
Optimer Pharmaceuticals
Basilea Pharmaceutica AG
Daiichi Sankyo
Outline of Major Chapters:
Chapter 1: Introduces the definition of Drugs for Anti-Infective, market overview.
Chapter 2: Global Drugs for Anti-Infective market size in revenue.
Chapter 3: Detailed analysis of Drugs for Anti-Infective company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Drugs for Anti-Infective in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Drugs for Anti-Infective Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Drugs for Anti-Infective Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Drugs for Anti-Infective Overall Market Size
2.1 Global Drugs for Anti-Infective Market Size: 2023 VS 2030
2.2 Global Drugs for Anti-Infective Market Size, Prospects & Forecasts: 2019-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Drugs for Anti-Infective Players in Global Market
3.2 Top Global Drugs for Anti-Infective Companies Ranked by Revenue
3.3 Global Drugs for Anti-Infective Revenue by Companies
3.4 Top 3 and Top 5 Drugs for Anti-Infective Companies in Global Market, by Revenue in 2023
3.5 Global Companies Drugs for Anti-Infective Product Type
3.6 Tier 1, Tier 2 and Tier 3 Drugs for Anti-Infective Players in Global Market
3.6.1 List of Global Tier 1 Drugs for Anti-Infective Companies
3.6.2 List of Global Tier 2 and Tier 3 Drugs for Anti-Infective Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Drugs for Anti-Infective Market Size Markets, 2023 & 2030
4.1.2 OTC
4.1.3 Rx Drugs
4.2 By Type - Global Drugs for Anti-Infective Revenue & Forecasts
4.2.1 By Type - Global Drugs for Anti-Infective Revenue, 2019-2024
4.2.2 By Type - Global Drugs for Anti-Infective Revenue, 2025-2030
4.2.3 By Type - Global Drugs for Anti-Infective Revenue Market Share, 2019-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Drugs for Anti-Infective Market Size, 2023 & 2030
5.1.2 Hospital
5.1.3 Drugs Store
5.1.4 Other
5.2 By Application - Global Drugs for Anti-Infective Revenue & Forecasts
5.2.1 By Application - Global Drugs for Anti-Infective Revenue, 2019-2024
5.2.2 By Application - Global Drugs for Anti-Infective Revenue, 2025-2030
5.2.3 By Application - Global Drugs for Anti-Infective Revenue Market Share, 2019-2030
6 Sights by Region
6.1 By Region - Global Drugs for Anti-Infective Market Size, 2023 & 2030
6.2 By Region - Global Drugs for Anti-Infective Revenue & Forecasts
6.2.1 By Region - Global Drugs for Anti-Infective Revenue, 2019-2024
6.2.2 By Region - Global Drugs for Anti-Infective Revenue, 2025-2030
6.2.3 By Region - Global Drugs for Anti-Infective Revenue Market Share, 2019-2030
6.3 North America
6.3.1 By Country - North America Drugs for Anti-Infective Revenue, 2019-2030
6.3.2 US Drugs for Anti-Infective Market Size, 2019-2030
6.3.3 Canada Drugs for Anti-Infective Market Size, 2019-2030
6.3.4 Mexico Drugs for Anti-Infective Market Size, 2019-2030
6.4 Europe
6.4.1 By Country - Europe Drugs for Anti-Infective Revenue, 2019-2030
6.4.2 Germany Drugs for Anti-Infective Market Size, 2019-2030
6.4.3 France Drugs for Anti-Infective Market Size, 2019-2030
6.4.4 U.K. Drugs for Anti-Infective Market Size, 2019-2030
6.4.5 Italy Drugs for Anti-Infective Market Size, 2019-2030
6.4.6 Russia Drugs for Anti-Infective Market Size, 2019-2030
6.4.7 Nordic Countries Drugs for Anti-Infective Market Size, 2019-2030
6.4.8 Benelux Drugs for Anti-Infective Market Size, 2019-2030
6.5 Asia
6.5.1 By Region - Asia Drugs for Anti-Infective Revenue, 2019-2030
6.5.2 China Drugs for Anti-Infective Market Size, 2019-2030
6.5.3 Japan Drugs for Anti-Infective Market Size, 2019-2030
6.5.4 South Korea Drugs for Anti-Infective Market Size, 2019-2030
6.5.5 Southeast Asia Drugs for Anti-Infective Market Size, 2019-2030
6.5.6 India Drugs for Anti-Infective Market Size, 2019-2030
6.6 South America
6.6.1 By Country - South America Drugs for Anti-Infective Revenue, 2019-2030
6.6.2 Brazil Drugs for Anti-Infective Market Size, 2019-2030
6.6.3 Argentina Drugs for Anti-Infective Market Size, 2019-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Drugs for Anti-Infective Revenue, 2019-2030
6.7.2 Turkey Drugs for Anti-Infective Market Size, 2019-2030
6.7.3 Israel Drugs for Anti-Infective Market Size, 2019-2030
6.7.4 Saudi Arabia Drugs for Anti-Infective Market Size, 2019-2030
6.7.5 UAE Drugs for Anti-Infective Market Size, 2019-2030
7 Drugs for Anti-Infective Companies Profiles
7.1 GlaxoSmithKline
7.1.1 GlaxoSmithKline Company Summary
7.1.2 GlaxoSmithKline Business Overview
7.1.3 GlaxoSmithKline Drugs for Anti-Infective Major Product Offerings
7.1.4 GlaxoSmithKline Drugs for Anti-Infective Revenue in Global Market (2019-2024)
7.1.5 GlaxoSmithKline Key News & Latest Developments
7.2 Merck
7.2.1 Merck Company Summary
7.2.2 Merck Business Overview
7.2.3 Merck Drugs for Anti-Infective Major Product Offerings
7.2.4 Merck Drugs for Anti-Infective Revenue in Global Market (2019-2024)
7.2.5 Merck Key News & Latest Developments
7.3 Pfizer
7.3.1 Pfizer Company Summary
7.3.2 Pfizer Business Overview
7.3.3 Pfizer Drugs for Anti-Infective Major Product Offerings
7.3.4 Pfizer Drugs for Anti-Infective Revenue in Global Market (2019-2024)
7.3.5 Pfizer Key News & Latest Developments
7.4 Novartis AG
7.4.1 Novartis AG Company Summary
7.4.2 Novartis AG Business Overview
7.4.3 Novartis AG Drugs for Anti-Infective Major Product Offerings
7.4.4 Novartis AG Drugs for Anti-Infective Revenue in Global Market (2019-2024)
7.4.5 Novartis AG Key News & Latest Developments
7.5 Gilead Sciences
7.5.1 Gilead Sciences Company Summary
7.5.2 Gilead Sciences Business Overview
7.5.3 Gilead Sciences Drugs for Anti-Infective Major Product Offerings
7.5.4 Gilead Sciences Drugs for Anti-Infective Revenue in Global Market (2019-2024)
7.5.5 Gilead Sciences Key News & Latest Developments
7.6 Abbott
7.6.1 Abbott Company Summary
7.6.2 Abbott Business Overview
7.6.3 Abbott Drugs for Anti-Infective Major Product Offerings
7.6.4 Abbott Drugs for Anti-Infective Revenue in Global Market (2019-2024)
7.6.5 Abbott Key News & Latest Developments
7.7 Sanofi-Aventis
7.7.1 Sanofi-Aventis Company Summary
7.7.2 Sanofi-Aventis Business Overview
7.7.3 Sanofi-Aventis Drugs for Anti-Infective Major Product Offerings
7.7.4 Sanofi-Aventis Drugs for Anti-Infective Revenue in Global Market (2019-2024)
7.7.5 Sanofi-Aventis Key News & Latest Developments
7.8 Bristol-Myers Squibb
7.8.1 Bristol-Myers Squibb Company Summary
7.8.2 Bristol-Myers Squibb Business Overview
7.8.3 Bristol-Myers Squibb Drugs for Anti-Infective Major Product Offerings
7.8.4 Bristol-Myers Squibb Drugs for Anti-Infective Revenue in Global Market (2019-2024)
7.8.5 Bristol-Myers Squibb Key News & Latest Developments
7.9 Johnson
7.9.1 Johnson Company Summary
7.9.2 Johnson Business Overview
7.9.3 Johnson Drugs for Anti-Infective Major Product Offerings
7.9.4 Johnson Drugs for Anti-Infective Revenue in Global Market (2019-2024)
7.9.5 Johnson Key News & Latest Developments
7.10 Roche Pharma AG
7.10.1 Roche Pharma AG Company Summary
7.10.2 Roche Pharma AG Business Overview
7.10.3 Roche Pharma AG Drugs for Anti-Infective Major Product Offerings
7.10.4 Roche Pharma AG Drugs for Anti-Infective Revenue in Global Market (2019-2024)
7.10.5 Roche Pharma AG Key News & Latest Developments
7.11 Nanosphere
7.11.1 Nanosphere Company Summary
7.11.2 Nanosphere Business Overview
7.11.3 Nanosphere Drugs for Anti-Infective Major Product Offerings
7.11.4 Nanosphere Drugs for Anti-Infective Revenue in Global Market (2019-2024)
7.11.5 Nanosphere Key News & Latest Developments
7.12 NanoViricides
7.12.1 NanoViricides Company Summary
7.12.2 NanoViricides Business Overview
7.12.3 NanoViricides Drugs for Anti-Infective Major Product Offerings
7.12.4 NanoViricides Drugs for Anti-Infective Revenue in Global Market (2019-2024)
7.12.5 NanoViricides Key News & Latest Developments
7.13 Novabay Pharmaceuticals
7.13.1 Novabay Pharmaceuticals Company Summary
7.13.2 Novabay Pharmaceuticals Business Overview
7.13.3 Novabay Pharmaceuticals Drugs for Anti-Infective Major Product Offerings
7.13.4 Novabay Pharmaceuticals Drugs for Anti-Infective Revenue in Global Market (2019-2024)
7.13.5 Novabay Pharmaceuticals Key News & Latest Developments
7.14 Obetech
7.14.1 Obetech Company Summary
7.14.2 Obetech Business Overview
7.14.3 Obetech Drugs for Anti-Infective Major Product Offerings
7.14.4 Obetech Drugs for Anti-Infective Revenue in Global Market (2019-2024)
7.14.5 Obetech Key News & Latest Developments
7.15 Optimer Pharmaceuticals
7.15.1 Optimer Pharmaceuticals Company Summary
7.15.2 Optimer Pharmaceuticals Business Overview
7.15.3 Optimer Pharmaceuticals Drugs for Anti-Infective Major Product Offerings
7.15.4 Optimer Pharmaceuticals Drugs for Anti-Infective Revenue in Global Market (2019-2024)
7.15.5 Optimer Pharmaceuticals Key News & Latest Developments
7.16 Basilea Pharmaceutica AG
7.16.1 Basilea Pharmaceutica AG Company Summary
7.16.2 Basilea Pharmaceutica AG Business Overview
7.16.3 Basilea Pharmaceutica AG Drugs for Anti-Infective Major Product Offerings
7.16.4 Basilea Pharmaceutica AG Drugs for Anti-Infective Revenue in Global Market (2019-2024)
7.16.5 Basilea Pharmaceutica AG Key News & Latest Developments
7.17 Daiichi Sankyo
7.17.1 Daiichi Sankyo Company Summary
7.17.2 Daiichi Sankyo Business Overview
7.17.3 Daiichi Sankyo Drugs for Anti-Infective Major Product Offerings
7.17.4 Daiichi Sankyo Drugs for Anti-Infective Revenue in Global Market (2019-2024)
7.17.5 Daiichi Sankyo Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Drugs for Anti-Infective Market Opportunities & Trends in Global Market
Table 2. Drugs for Anti-Infective Market Drivers in Global Market
Table 3. Drugs for Anti-Infective Market Restraints in Global Market
Table 4. Key Players of Drugs for Anti-Infective in Global Market
Table 5. Top Drugs for Anti-Infective Players in Global Market, Ranking by Revenue (2023)
Table 6. Global Drugs for Anti-Infective Revenue by Companies, (US$, Mn), 2019-2024
Table 7. Global Drugs for Anti-Infective Revenue Share by Companies, 2019-2024
Table 8. Global Companies Drugs for Anti-Infective Product Type
Table 9. List of Global Tier 1 Drugs for Anti-Infective Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Drugs for Anti-Infective Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 11. By Type ? Global Drugs for Anti-Infective Revenue, (US$, Mn), 2023 & 2030
Table 12. By Type - Drugs for Anti-Infective Revenue in Global (US$, Mn), 2019-2024
Table 13. By Type - Drugs for Anti-Infective Revenue in Global (US$, Mn), 2025-2030
Table 14. By Application ? Global Drugs for Anti-Infective Revenue, (US$, Mn), 2023 & 2030
Table 15. By Application - Drugs for Anti-Infective Revenue in Global (US$, Mn), 2019-2024
Table 16. By Application - Drugs for Anti-Infective Revenue in Global (US$, Mn), 2025-2030
Table 17. By Region ? Global Drugs for Anti-Infective Revenue, (US$, Mn), 2023 & 2030
Table 18. By Region - Global Drugs for Anti-Infective Revenue (US$, Mn), 2019-2024
Table 19. By Region - Global Drugs for Anti-Infective Revenue (US$, Mn), 2025-2030
Table 20. By Country - North America Drugs for Anti-Infective Revenue, (US$, Mn), 2019-2024
Table 21. By Country - North America Drugs for Anti-Infective Revenue, (US$, Mn), 2025-2030
Table 22. By Country - Europe Drugs for Anti-Infective Revenue, (US$, Mn), 2019-2024
Table 23. By Country - Europe Drugs for Anti-Infective Revenue, (US$, Mn), 2025-2030
Table 24. By Region - Asia Drugs for Anti-Infective Revenue, (US$, Mn), 2019-2024
Table 25. By Region - Asia Drugs for Anti-Infective Revenue, (US$, Mn), 2025-2030
Table 26. By Country - South America Drugs for Anti-Infective Revenue, (US$, Mn), 2019-2024
Table 27. By Country - South America Drugs for Anti-Infective Revenue, (US$, Mn), 2025-2030
Table 28. By Country - Middle East & Africa Drugs for Anti-Infective Revenue, (US$, Mn), 2019-2024
Table 29. By Country - Middle East & Africa Drugs for Anti-Infective Revenue, (US$, Mn), 2025-2030
Table 30. GlaxoSmithKline Company Summary
Table 31. GlaxoSmithKline Drugs for Anti-Infective Product Offerings
Table 32. GlaxoSmithKline Drugs for Anti-Infective Revenue (US$, Mn) & (2019-2024)
Table 33. GlaxoSmithKline Key News & Latest Developments
Table 34. Merck Company Summary
Table 35. Merck Drugs for Anti-Infective Product Offerings
Table 36. Merck Drugs for Anti-Infective Revenue (US$, Mn) & (2019-2024)
Table 37. Merck Key News & Latest Developments
Table 38. Pfizer Company Summary
Table 39. Pfizer Drugs for Anti-Infective Product Offerings
Table 40. Pfizer Drugs for Anti-Infective Revenue (US$, Mn) & (2019-2024)
Table 41. Pfizer Key News & Latest Developments
Table 42. Novartis AG Company Summary
Table 43. Novartis AG Drugs for Anti-Infective Product Offerings
Table 44. Novartis AG Drugs for Anti-Infective Revenue (US$, Mn) & (2019-2024)
Table 45. Novartis AG Key News & Latest Developments
Table 46. Gilead Sciences Company Summary
Table 47. Gilead Sciences Drugs for Anti-Infective Product Offerings
Table 48. Gilead Sciences Drugs for Anti-Infective Revenue (US$, Mn) & (2019-2024)
Table 49. Gilead Sciences Key News & Latest Developments
Table 50. Abbott Company Summary
Table 51. Abbott Drugs for Anti-Infective Product Offerings
Table 52. Abbott Drugs for Anti-Infective Revenue (US$, Mn) & (2019-2024)
Table 53. Abbott Key News & Latest Developments
Table 54. Sanofi-Aventis Company Summary
Table 55. Sanofi-Aventis Drugs for Anti-Infective Product Offerings
Table 56. Sanofi-Aventis Drugs for Anti-Infective Revenue (US$, Mn) & (2019-2024)
Table 57. Sanofi-Aventis Key News & Latest Developments
Table 58. Bristol-Myers Squibb Company Summary
Table 59. Bristol-Myers Squibb Drugs for Anti-Infective Product Offerings
Table 60. Bristol-Myers Squibb Drugs for Anti-Infective Revenue (US$, Mn) & (2019-2024)
Table 61. Bristol-Myers Squibb Key News & Latest Developments
Table 62. Johnson Company Summary
Table 63. Johnson Drugs for Anti-Infective Product Offerings
Table 64. Johnson Drugs for Anti-Infective Revenue (US$, Mn) & (2019-2024)
Table 65. Johnson Key News & Latest Developments
Table 66. Roche Pharma AG Company Summary
Table 67. Roche Pharma AG Drugs for Anti-Infective Product Offerings
Table 68. Roche Pharma AG Drugs for Anti-Infective Revenue (US$, Mn) & (2019-2024)
Table 69. Roche Pharma AG Key News & Latest Developments
Table 70. Nanosphere Company Summary
Table 71. Nanosphere Drugs for Anti-Infective Product Offerings
Table 72. Nanosphere Drugs for Anti-Infective Revenue (US$, Mn) & (2019-2024)
Table 73. Nanosphere Key News & Latest Developments
Table 74. NanoViricides Company Summary
Table 75. NanoViricides Drugs for Anti-Infective Product Offerings
Table 76. NanoViricides Drugs for Anti-Infective Revenue (US$, Mn) & (2019-2024)
Table 77. NanoViricides Key News & Latest Developments
Table 78. Novabay Pharmaceuticals Company Summary
Table 79. Novabay Pharmaceuticals Drugs for Anti-Infective Product Offerings
Table 80. Novabay Pharmaceuticals Drugs for Anti-Infective Revenue (US$, Mn) & (2019-2024)
Table 81. Novabay Pharmaceuticals Key News & Latest Developments
Table 82. Obetech Company Summary
Table 83. Obetech Drugs for Anti-Infective Product Offerings
Table 84. Obetech Drugs for Anti-Infective Revenue (US$, Mn) & (2019-2024)
Table 85. Obetech Key News & Latest Developments
Table 86. Optimer Pharmaceuticals Company Summary
Table 87. Optimer Pharmaceuticals Drugs for Anti-Infective Product Offerings
Table 88. Optimer Pharmaceuticals Drugs for Anti-Infective Revenue (US$, Mn) & (2019-2024)
Table 89. Optimer Pharmaceuticals Key News & Latest Developments
Table 90. Basilea Pharmaceutica AG Company Summary
Table 91. Basilea Pharmaceutica AG Drugs for Anti-Infective Product Offerings
Table 92. Basilea Pharmaceutica AG Drugs for Anti-Infective Revenue (US$, Mn) & (2019-2024)
Table 93. Basilea Pharmaceutica AG Key News & Latest Developments
Table 94. Daiichi Sankyo Company Summary
Table 95. Daiichi Sankyo Drugs for Anti-Infective Product Offerings
Table 96. Daiichi Sankyo Drugs for Anti-Infective Revenue (US$, Mn) & (2019-2024)
Table 97. Daiichi Sankyo Key News & Latest Developments
List of Figures
Figure 1. Drugs for Anti-Infective Segment by Type in 2023
Figure 2. Drugs for Anti-Infective Segment by Application in 2023
Figure 3. Global Drugs for Anti-Infective Market Overview: 2023
Figure 4. Key Caveats
Figure 5. Global Drugs for Anti-Infective Market Size: 2023 VS 2030 (US$, Mn)
Figure 6. Global Drugs for Anti-Infective Revenue, 2019-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Drugs for Anti-Infective Revenue in 2023
Figure 8. By Type - Global Drugs for Anti-Infective Revenue Market Share, 2019-2030
Figure 9. By Application - Global Drugs for Anti-Infective Revenue Market Share, 2019-2030
Figure 10. By Type - Global Drugs for Anti-Infective Revenue, (US$, Mn), 2023 & 2030
Figure 11. By Type - Global Drugs for Anti-Infective Revenue Market Share, 2019-2030
Figure 12. By Application - Global Drugs for Anti-Infective Revenue, (US$, Mn), 2023 & 2030
Figure 13. By Application - Global Drugs for Anti-Infective Revenue Market Share, 2019-2030
Figure 14. By Region - Global Drugs for Anti-Infective Revenue Market Share, 2019-2030
Figure 15. By Country - North America Drugs for Anti-Infective Revenue Market Share, 2019-2030
Figure 16. US Drugs for Anti-Infective Revenue, (US$, Mn), 2019-2030
Figure 17. Canada Drugs for Anti-Infective Revenue, (US$, Mn), 2019-2030
Figure 18. Mexico Drugs for Anti-Infective Revenue, (US$, Mn), 2019-2030
Figure 19. By Country - Europe Drugs for Anti-Infective Revenue Market Share, 2019-2030
Figure 20. Germany Drugs for Anti-Infective Revenue, (US$, Mn), 2019-2030
Figure 21. France Drugs for Anti-Infective Revenue, (US$, Mn), 2019-2030
Figure 22. U.K. Drugs for Anti-Infective Revenue, (US$, Mn), 2019-2030
Figure 23. Italy Drugs for Anti-Infective Revenue, (US$, Mn), 2019-2030
Figure 24. Russia Drugs for Anti-Infective Revenue, (US$, Mn), 2019-2030
Figure 25. Nordic Countries Drugs for Anti-Infective Revenue, (US$, Mn), 2019-2030
Figure 26. Benelux Drugs for Anti-Infective Revenue, (US$, Mn), 2019-2030
Figure 27. By Region - Asia Drugs for Anti-Infective Revenue Market Share, 2019-2030
Figure 28. China Drugs for Anti-Infective Revenue, (US$, Mn), 2019-2030
Figure 29. Japan Drugs for Anti-Infective Revenue, (US$, Mn), 2019-2030
Figure 30. South Korea Drugs for Anti-Infective Revenue, (US$, Mn), 2019-2030
Figure 31. Southeast Asia Drugs for Anti-Infective Revenue, (US$, Mn), 2019-2030
Figure 32. India Drugs for Anti-Infective Revenue, (US$, Mn), 2019-2030
Figure 33. By Country - South America Drugs for Anti-Infective Revenue Market Share, 2019-2030
Figure 34. Brazil Drugs for Anti-Infective Revenue, (US$, Mn), 2019-2030
Figure 35. Argentina Drugs for Anti-Infective Revenue, (US$, Mn), 2019-2030
Figure 36. By Country - Middle East & Africa Drugs for Anti-Infective Revenue Market Share, 2019-2030
Figure 37. Turkey Drugs for Anti-Infective Revenue, (US$, Mn), 2019-2030
Figure 38. Israel Drugs for Anti-Infective Revenue, (US$, Mn), 2019-2030
Figure 39. Saudi Arabia Drugs for Anti-Infective Revenue, (US$, Mn), 2019-2030
Figure 40. UAE Drugs for Anti-Infective Revenue, (US$, Mn), 2019-2030
Figure 41. GlaxoSmithKline Drugs for Anti-Infective Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 42. Merck Drugs for Anti-Infective Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 43. Pfizer Drugs for Anti-Infective Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 44. Novartis AG Drugs for Anti-Infective Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 45. Gilead Sciences Drugs for Anti-Infective Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 46. Abbott Drugs for Anti-Infective Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 47. Sanofi-Aventis Drugs for Anti-Infective Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 48. Bristol-Myers Squibb Drugs for Anti-Infective Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 49. Johnson Drugs for Anti-Infective Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 50. Roche Pharma AG Drugs for Anti-Infective Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 51. Nanosphere Drugs for Anti-Infective Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 52. NanoViricides Drugs for Anti-Infective Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 53. Novabay Pharmaceuticals Drugs for Anti-Infective Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 54. Obetech Drugs for Anti-Infective Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 55. Optimer Pharmaceuticals Drugs for Anti-Infective Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 56. Basilea Pharmaceutica AG Drugs for Anti-Infective Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 57. Daiichi Sankyo Drugs for Anti-Infective Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
